Reducing the Risk of Recurrence In HR+/HER2- Early Breast Cancer Requires Action: MDT Clinical Ca...

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 InhibitorsПодробнее

Managing the Borderline-Risk Patient With Hormone Receptor-Positive/HER2-Negative Early Breast Ca...Подробнее

Defining Optimal Therapy in High-Risk Early Breast Cancer #shortsПодробнее

Communicating the Risk of Recurrence for Patients With HR+, HER2- Early Breast CancerПодробнее

The impact of pregnancy on recurrence scores in ER+/HER2- breast cancerПодробнее

Reduce the Risk of Recurrence with Nerlynx | Webinar on Therapeutic Decision-makingПодробнее

Early breast cancer: do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)?Подробнее

Reduce the Risk of Recurrence in Early Stage HER2+ Breast CancerПодробнее

Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast CancerПодробнее

Assessing Risk in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: How to Approach Ch...Подробнее

Reducing Risk in Residual Breast CancerПодробнее

ADAPT trial: Endocrine + ribociclib vs. chemotherapy in HR+/HER2- early breast cancerПодробнее

Conceptualizing Guidelines to Manage Patients with HR–Positive, HER2-Negative Early Breast CancerПодробнее

Outcome in Mind: Applying Best Practices for Managing HR+/HER2- EBC at High Risk of RecurrenceПодробнее

Early Breast Cancer: HR+/HER2- - New Study ResultsПодробнее

N9831 trial: genes associated with early and late recurrence in HER2+ breast cancerПодробнее

Depu Tripathy on Lower Risk for Recurrence of Early Stage Breast CancerПодробнее

Prognostic score in early HR+/HER2- breast cancer: RS, factors, mutations, histologyПодробнее

Recent Updates in HR-Positive/HER2-Negative Early Breast Cancer: A Deep Dive Into Understanding t...Подробнее